Breaking Finance News

Axsome Therapeutics Inc (NASDAQ:AXSM) target price raised to $4.50, reported today by Zacks Investment Research

Just yesterday Axsome Therapeutics Inc (NASDAQ:AXSM) traded 2.78% higher at $4.10. Axsome Therapeutics Inc’s 50-day moving average is $5.14 and its 200-day moving average is $4.68. The last stock price is down 18.62% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 47,956 shares of AXSM traded hands, down from an average trading volume of 213,656

Axsome Therapeutics Inc (NASDAQ:AXSM) had its target price raised to $4.50 by Zacks Investment Research in a report released 6/19/2017. The updated stock price target implies a possible upside of 0.10% based on the company's previous stock price.

Recent Performance Chart

Axsome Therapeutics Inc (NASDAQ:AXSM)

Axsome Therapeutics Inc has 52 week low of $3.53 and a 52 week high of $9.11 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokerages have issued a research note on the company. The average stock price target is $23.00 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Axsome Therapeutics Inc (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.